In the past four weeks, the world greeted the continual positive findings from several late-stage Covid-19 vaccine trials with loud cheers. Global stock markets rallied, and the surge in share prices of aviation and tourism counters revealed the widespread optimism of the world about a return to pre-Covid-19 normalcy.

This enthusiasm is reinforced whenever governments worldwide announce their plans to procure and deliver the vaccines, regardless of the important caveat to prioritise limited vaccine doses for front-line workers and high-risk groups before mass distribution to the rest of the population is possible.